Alcobra Ltd. to Present at the Gordon Research Conference on Fragile X and Autism-Related Disorders
May 23, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, May 23, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
Alcobra Announces First Quarter Financial Results and Corporate Update
May 15, 2014 07:30 ET
|
Alcobra Ltd.
TEL AVIV, Israel, May 15, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
Alcobra Ltd. Presents Evidence of Novel Mechanism of Action for Metadoxine Extended Release (MDX) in Cognitive Disorders at the Society of Biological Psychiatry Annual Meeting
May 12, 2014 08:00 ET
|
Alcobra Ltd.
-- Improvements in cognitive performance in animal models are consistent with MDX effects in human adults with ADHD –
-- Metadoxine has effects on neurotransmitters associated with...
Alcobra Announces FDA Clearance of Protocol for Phase IIb Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome
May 08, 2014 12:20 ET
|
Alcobra Ltd.
TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Ltd. to Provide Corporate Overview at Oppenheimer and BioMed Conferences
May 08, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
Alcobra Ltd. to Release First Quarter 2014 Results and Host Investor Conference Call on Thursday, May 15, 2014
May 07, 2014 16:05 ET
|
Alcobra Ltd.
TEL AVIV, Israel, May 7, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly Inattentive ADHD at APA Annual Meeting
May 05, 2014 08:00 ET
|
Alcobra Ltd.
MDX produced statistically significant improvement (p < 0.01) on the primary endpoint compared to placebo
MDX was superior to placebo after a single dose while demonstrating a safety...
Alcobra Issued New US Patent Covering Metadoxine Use for Cognitive Disorders
May 01, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, May 1, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
Alcobra Ltd. to Present New Data for Metadoxine Extended Release (MDX) at Upcoming Meetings
April 24, 2014 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, April 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome
April 10, 2014 12:30 ET
|
Alcobra Ltd.
TEL AVIV, Israel, April 10, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...